Literature DB >> 27502919

The untold story of IFN-γ in cancer biology.

M Alper Kursunel1, Gunes Esendagli2.   

Abstract

Interferon (IFN)-γ is the uppermost cytokine implicated in anti-tumor immunity. With its cytostatic, pro-apoptotic and immune-provoking effects, IFN-γ plays a central role in the recognition and elimination of transformed cells. Considering well-characterized anti-tumor effects of this cytokine, many clinical trials and immunotherapy approaches have been designed to reinforce IFN-γ-mediated immunity for different types of cancer. However, the outcomes were not satisfactory and leaded to questioning of alternative actions of IFN-γ. Many regulatory pathways can be induced by IFN-γ to protect the normal tissues from collateral damage and to facilitate the re-establishment of homeostasis. Nevertheless, malignant cells can take the advantage of IFN-γ as an inducer of mediators inhibiting anti-tumor immune reactions. In addition, under the influence of tumor-derived factors, certain types of immune cells are also licensed by IFN-γ to perform regulatory actions. This review focuses on the immune modulatory functions of IFN-γ in cancer as an alternative story to be told.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-tumor immunity; Cancer; Immune regulation; Immunotherapy; Interferon; Myeloid cell; T cell

Mesh:

Substances:

Year:  2016        PMID: 27502919     DOI: 10.1016/j.cytogfr.2016.07.005

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  45 in total

1.  In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.

Authors:  Abner A Murray; Chao Wang; Steven Fiering; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-25       Impact factor: 4.939

2.  Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.

Authors:  Debra D Bloom; Sofiya Reshetylo; Cassandra Nytes; Claudia T Goodsett; Peiman Hematti
Journal:  J Immunother       Date:  2018-06       Impact factor: 4.456

Review 3.  Tumor Immunology meets…Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells.

Authors:  Farah Bou Nasser Eddine; Elise Ramia; Giovanna Tosi; Greta Forlani; Roberto S Accolla
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

4.  Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma.

Authors:  Lixiao Liu; Xuedan Du; Jintao Fang; Jinduo Zhao; Yong Guo; Ye Zhao; Chengyang Zou; Xiaojian Yan; Wenfeng Li
Journal:  J Inflamm Res       Date:  2021-09-27

5.  The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer.

Authors:  Kimiya Shams; Mohaddeseh Larypoor; Jafar Salimian
Journal:  Med Oncol       Date:  2021-10-12       Impact factor: 3.064

6.  Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients.

Authors:  Jing Liu; Jingtao Ma; Na Xing; Zhengzheng Ji; Jiasong Li; Shasha Zhang; Zhanjun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-19       Impact factor: 4.322

7.  The Interferon-Gamma Paradox in Cancer.

Authors:  M Raza Zaidi
Journal:  J Interferon Cytokine Res       Date:  2018-11-09       Impact factor: 2.607

Review 8.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

9.  Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo.

Authors:  Syed Umar Faruq Syed Najmuddin; Zahiah Mohamed Amin; Sheau Wei Tan; Swee Keong Yeap; Jeevanathan Kalyanasundram; Muhamad Alhapis Che Ani; Abhimanyu Veerakumarasivam; Soon Choy Chan; Suet Lin Chia; Khatijah Yusoff; Noorjahan Banu Alitheen
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

10.  IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.

Authors:  Wenli Yuan; Deyao Deng; Hanyu Li; Xinghui Hu; Xueqin Shang; Xia Hou; Hongchao Jiang; Hongchun He
Journal:  Onco Targets Ther       Date:  2021-05-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.